AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 201 min read$MYGN

Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210 Million Plus Inventory

Myriad Genetics (MYGN) agreed to sell its prenatal health business to Labcorp (LH) for $210M in cash plus inventory value. The deal includes several prenatal tests and is subject to regulatory approvals, with a closing deadline of Feb 19, 2027, extendable to Oct 19, 2027. A patent license agreement was also signed to support the transaction.

Original reporting
tradingview.com
Published Oct 20, 2026, 12:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210 Million Plus Inventory — source image
Source · tradingview.com
Decision brief

The 30-second read

$MYGNBearishMed
01

Why it matters

The transaction is a material M&A event for both companies, likely influencing their share prices and the competitive landscape in prenatal diagnostics.

02

Market read

A $210 million asset sale that could reshape revenue streams for Myriad and expand Labcorp's test menu, affecting investor sentiment in the healthcare sector.

03

What to watch

Regulatory approvals and HSR clearance could delay closing, adding execution risk to the transaction.

Relevance 8/10Novelty 8/10Timing: today

Background

Myriad Genetics is divesting its prenatal testing segment to refocus on core genetics offerings, while Labcorp seeks to broaden its diagnostic portfolio.

Company-level read

Ticker impact

$MYGNBearishHigh confidence
Context

Myriad Genetics announced an asset sale of its prenatal testing business to Labcorp for $210 million plus inventory.

Expected impact

likely downside as the market prices in the loss of the prenatal segment.

Evidence & confidence

The deal size is material and the sale removes a business line, which typically weighs on the seller's stock.

$LHBullishHigh confidence
Context

Labcorp agreed to acquire Myriad Genetics' prenatal testing business for $210 million plus inventory.

Expected impact

likely upside as the market values the added product suite and revenue potential.

Evidence & confidence

A cash‑plus‑inventory acquisition of a niche testing business is viewed as a strategic growth move for Labcorp.

Market effects

Sector

The deal signals consolidation in the prenatal diagnostics market, potentially prompting other players to consider similar acquisitions.

Regional

Both companies are U.S.-based; the transaction has limited direct regional impact beyond the U.S. healthcare sector.

Global

Adds to the broader trend of healthcare companies expanding diagnostic capabilities globally.

Counterpoint

What could challenge this read

The sale could free Myriad to focus on higher‑margin genetics services, mitigating the negative impact on its stock.

Key entities

  • company
    Myriad Genetics

    Seller of the prenatal testing business.

  • company
    Labcorp

    Buyer acquiring the prenatal testing assets.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

6 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min